RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: A possible step forward?

Oncology (Switzerland)

Volumn 88, Issue 4, 2014, Pages 257-260

  Cathomas, Richard ^a   Rothermundt, Christian ^a   Bode, Beata ^b   Fuchs, Bruno ^c   Von Moos, Roger ^a   Schwitter, Michael ^a  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Denosumab; Osteosarcoma; RANK; RANK ligand; Sorafenib

Indexed keywords

CARBOPLATIN; CISPLATIN; DENOSUMAB; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; MONOCLONAL ANTIBODY; NICOTINAMIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG MEGADOSE; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; PRIORITY JOURNAL; SEVENTH CERVICAL VERTEBRA; STEREOTACTIC TREATMENT; TUMOR GROWTH; TUMOR REGRESSION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; PATHOLOGY; PROGNOSIS; REMISSION; SALVAGE THERAPY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NIACINAMIDE; OSTEOSARCOMA; PHENYLUREA COMPOUNDS; PROGNOSIS; RANK LIGAND; REMISSION INDUCTION; SALVAGE THERAPY;

EID: 84926419149     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000369975     Document Type: Article

References (19)

1. Anninga JK, Gelderblom H, Fiocco M, et al: Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 2011; 47: 2431-2445.
2. Schoenfeld AJ, Hornicek FJ, Pedlow FX, et al: Osteosarcoma of the spine: experience in 26 patients treated at the Massachusetts General Hospital. Spine J 2010; 10: 708-714.
3. Collins M, Wilhelm M, Conyers R, et al: Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol 2013; 31: 2303-2312.
4. Bielack SS, Kempf-Bielack B, Branscheid D, et al: Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol 2009; 27: 557-565.
5. Grignani G, Palmerini E, Dileo P, et al: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012; 23: 508-516.
6. Dougall WC, Glaccum M, Charrier K, et al: RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13: 2412-2424.
7. Beristain AG, Narala SR, Di Grappa MA, Khokha R: Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci 2012; 125: 943-955.
8. Lamoureux F, Richard P, Wittrand Y, et al: Therapeutic relevance of osteoprotegrin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res 2007; 67: 7308-7318.
9. Akiyama T, Choong PF, Dass CR: RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells. Clin Exp Metastasis 2010; 27: 207-215.
10. Lamoureux F, Picarda G, Rousseau J, et al: Therapeutic efficacy of soluble receptor activator of nuclear factor-?B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther 2008; 7: 3389-3398.
11. Akiyama T, Dass CR, Shinoda Y, et al: Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma in a murine model via activity against osteoclasts. J Pharm Pharmacol 2010; 62: 470-476.
12. EURAMOS 1: A randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy (ISRCTN67613327).
13. Bago-Horvath Y, Schmid K, Rosseler F, et al: Impact of RANK signaling on survival and chemotherapy response in osteosarcoma. Pathology 2014; 46: 411-415.
14. Lee JA, Jung JS, Kim DH, et al: RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer 2011; 56: 738-743.
15. Lacey DL, Boyle WJ, Simonet WS, et al: Bench to bedside: elucidation of the OPG-RANKRANKL pathway and the development of denosumab. Nat Rev Drug Discov 2012; 11: 401-419.
16. Peddi P, Lopez-Olivo MA, Pratt GF, et al: Denosumab in patients with cancer and skeletal metastases: a systematic review and metaanalysis. Cancer Treat Rev 2013; 39: 97-104.
17. Chawla S, Henshaw R, Seeger L: Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14: 901-908.
18. Pignochino Y, Grignani G, Cavalloni G, et al: Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009; 8: 118.
19. Mei J, Zhu X, Wang Y, Wang Z: VEGFR, RET and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment. Cell Biochem Biophys 2014; 69: 151-156.